ÎÚÑ»´«Ã½

Skip to main content
You have permission to edit this article.
Edit

B.C. limits sales of two more diabetes drugs amid off-label use for weight loss

The limits on sales of tirzepatide and dulaglutide come after a 2023 regulation limited sales of semaglutide, which is sold under the brand name Ozempic.

Updated
1 min read
B.C. limits sales of two more diabetes drugs amid off-label use for weight loss

British Columbia’s health minister Josie Osborne says “now is the time” for American doctors and nurses to move to the province as it fast tracks recognition of their credentials during an escalating trade war between Canada and the United States. Osborne, speaks during a news conference in Burnaby, B.C., on Monday, June 10, 2024. 


VICTORIA - British Columbia’s Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

The limits on sales of Type 2 diabetes drugs tirzepatide and dulaglutide come after a 2023 regulation limited sales of semaglutide, which is sold under the band name Ozempic.

ARTICLE CONTINUES BELOW

More from The Star & partners

JOIN THE CONVERSATION

To join the conversation set a first and last name in your user profile.

Conversations are opinions of our readers and are subject to the Community Guidelines. ÎÚÑ»´«Ã½ Star does not endorse these opinions.